Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH56 in MTAP-Deleted Advanced Solid Tumors
NCT06796699Phase 1Recruiting
- Sponsor
- Genhouse Bio
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GH-56 in solid tumor (advanced stage), sponsored by Genhouse Bio. Primary endpoints: Maximum Tolerated Dose at 3 years, Recommended Dose for Expansion at 3 years and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
GH-56
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06796699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796699.